EA200702079A1 - Вакцина - Google Patents

Вакцина

Info

Publication number
EA200702079A1
EA200702079A1 EA200702079A EA200702079A EA200702079A1 EA 200702079 A1 EA200702079 A1 EA 200702079A1 EA 200702079 A EA200702079 A EA 200702079A EA 200702079 A EA200702079 A EA 200702079A EA 200702079 A1 EA200702079 A1 EA 200702079A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hpv
vaccine
protein
immunogenic fragment
vaccines
Prior art date
Application number
EA200702079A
Other languages
English (en)
Other versions
EA013326B1 (ru
Inventor
Брижитт Дезире Альберт Коло
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36992675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200702079(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0509010A external-priority patent/GB0509010D0/en
Priority claimed from PCT/EP2005/006461 external-priority patent/WO2005123125A1/en
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA200702079A1 publication Critical patent/EA200702079A1/ru
Publication of EA013326B1 publication Critical patent/EA013326B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Способ предупреждения HPV-инфекции и/или заболевания, включающий доставку первой HPV-вакцины, содержащей белок L1 или его иммуногенный фрагмент по меньшей мере из HPV 16 и HPV 18, и второй HPV-вакцины, которая не содержит компоненты L1 HPV 16 и HPV 18 первой вакцины и которая содержит белок L1 или его иммуногенный фрагмент по меньшей мере из одного другого онкогенного HPV-типа, где первая и вторая вакцины могут быть доставлены в любой последовательности, и доставки осуществляют через подходящий интервал времени.
EA200702079A 2005-04-26 2006-04-24 Вакцина EA013326B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67482905P 2005-04-26 2005-04-26
GB0509010A GB0509010D0 (en) 2005-05-03 2005-05-03 Vaccine
PCT/EP2005/006461 WO2005123125A1 (en) 2004-06-16 2005-06-14 Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
PCT/EP2006/003918 WO2006114312A2 (en) 2005-04-26 2006-04-24 Vaccine

Publications (2)

Publication Number Publication Date
EA200702079A1 true EA200702079A1 (ru) 2008-04-28
EA013326B1 EA013326B1 (ru) 2010-04-30

Family

ID=36992675

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702079A EA013326B1 (ru) 2005-04-26 2006-04-24 Вакцина

Country Status (12)

Country Link
US (1) US20090181052A1 (ru)
EP (1) EP1877086A2 (ru)
JP (1) JP2008539184A (ru)
KR (1) KR20080005585A (ru)
AR (1) AR054259A1 (ru)
AU (1) AU2006239422A1 (ru)
CA (1) CA2606092A1 (ru)
EA (1) EA013326B1 (ru)
MX (1) MX2007013472A (ru)
NO (1) NO20075194L (ru)
SG (1) SG159525A1 (ru)
WO (1) WO2006114312A2 (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
BRPI0916732B1 (pt) * 2008-07-31 2021-06-29 Glaxosmithkline Biologicals S.A. Vacina para a prevenção de doença ou infecção relacionada ao papilomavirus humano (hpv) compreendendo partículas semelhantes ao vírus hpv 16 e hpv 18
PL2444103T3 (pl) * 2009-06-19 2018-05-30 Eyegene Inc. Szczepionka przeciwko rakowi szyjki macicy
AU2012272788B2 (en) 2011-06-24 2016-10-20 Merck Sharp & Dohme Llc HPV vaccine formulations comprising aluminum adjuvant and methods of producing same
EP4103227A1 (en) 2020-02-14 2022-12-21 Merck Sharp & Dohme LLC Hpv vaccine
WO2023014853A1 (en) 2021-08-06 2023-02-09 Merck Sharp & Dohme Llc Hpv vaccine
CN118019547A (zh) 2021-08-19 2024-05-10 默沙东有限责任公司 热稳定脂质纳米粒子及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
GB0105606D0 (en) * 2001-03-07 2001-04-25 Cantab Pharmaceuticals Res Ltd Immunogens and vaccines and their preparation and use
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
EP1572233B1 (en) * 2002-12-20 2011-03-30 GlaxoSmithKline Biologicals s.a. Use of HPV16 and HPV18 as vaccine against one or more of oncogenic HPV type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast

Also Published As

Publication number Publication date
MX2007013472A (es) 2008-04-02
AR054259A1 (es) 2007-06-13
JP2008539184A (ja) 2008-11-13
EP1877086A2 (en) 2008-01-16
NO20075194L (no) 2008-01-18
WO2006114312A3 (en) 2007-04-05
EA013326B1 (ru) 2010-04-30
AU2006239422A1 (en) 2006-11-02
WO2006114312A2 (en) 2006-11-02
CA2606092A1 (en) 2006-11-02
US20090181052A1 (en) 2009-07-16
SG159525A1 (en) 2010-03-30
KR20080005585A (ko) 2008-01-14

Similar Documents

Publication Publication Date Title
EA200702079A1 (ru) Вакцина
CY1121211T1 (el) Εμβολιο ιου ερπητα ζωστηρα
MXPA05009580A (es) Vacuna contra el virus de la influenza.
FR20C1016I1 (ru)
WO2006115843A3 (en) Nipah virus vaccines
EA200802170A1 (ru) Лиофилизированная композиция терапевтического пептидного антитела
EP2526966A3 (en) Herpes simplex virus combined subunit vaccines and methods of use thereof
EP2606933A3 (en) Combination of an IAP-inhibitor and a taxane
SG156652A1 (en) Yeast-based therapeutic for chronic hepatitis c infection
IN2015KN00290A (ru)
WO2006065553A3 (en) Glycoconjugate vaccines containing peptidoglycan
WO2007002470A3 (en) Inactivated chimeric vaccines and related methods of use
MXPA06013388A (es) Vector lentiviral recombinante para la expresion de una proteina flaviviridae y sus aplicaciones como vacuna.
CY1112158T1 (el) Yπoδoxeaς γia xophγoymena yγpa φapmaka
FR2827605B1 (fr) Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
GB2453491A (en) Immunogenic proteins of burkholderia pseudomallei and uses thereof
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
WO2005007673A3 (en) Immunogenic peptides
WO2006071896A3 (en) Epitope-based sars vaccine
EA200701166A1 (ru) Альфа-тимозиновые пептиды в качестве адъювантов противораковых вакцин
DE60331412D1 (de) Hiv-vakzine und anwendungsverfahren
ATE443527T1 (de) 5-cnac zur oralen verabreichung von parathormonfragmenten
CL2010001175A1 (es) Composicion de vacuna que comprende un antigeno de proteina viral 2 (vp-2) del virus causante de la enfermedad de la bursitis infecciosa (ibdv).
WO2003093298A3 (en) Immunogenic peptides
TNSN08184A1 (en) Chimeric antigens and vaccines

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU